Cyclo-Progynova (Norgestrel, Estradiol) 21 pills

Cyclo-Progynova (Norgestrel, Estradiol) 21 pills

SKU:1961
To favorites
Cyclo-Progynova (Norgestrel, Estradiol)
Active substance:Norgestrel, Estradiol
Pharmacological group:Hormonal disorders
Formulation:Tablets
Dosage mg:0.5
In stock
$45
11
Description
Features
Reviews

Instructions for Cyclo-Progynova (Norgestrel, Estradiol) 21 pills

English product name
Cyclo-Progynova

Release form
Shell Tablet Kit

Description Cyclo-Progynova:

A set of tablets covered with a shell of two kinds.
The tablets, covered with a shell of white color, round, double-convex (11 pcs. in blister).

1 tab.
estradiol valerate, micro 20 2 mg

Auxiliary substances:

  • lactose monohydrate,
  • cornstarch,
  • povidon 25 thousand,
  • talc, magnesium stearate,
  • sucrose, povidon 90 thousand,
  • macrogol 6000,
  • calcium carbonate,
  • talc, wax mountain glycolic.
  • The tablets, covered with a shell of light brown color, round, double-convex (10 pcs. in blister).

1 tab.

  • norgestrel, micro 20 0.5 mg
  • estradiol valerate, micro 20 2 mg

Auxiliary substances:
lactose monohydrate, cornstarch, povidone 25 thousand, talc, magnesium stearate, sucrose, povidone 90 thousand, macrogol 6000, calcium carbonate, talc, glycerol 85%, mountain glycolic wax, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172).

21 pcs. (10 and 11 pcs.) - blisters (1) with self-adhesive calendar of reception - cardboard boxes with first opening control.

ATC codes
G03AA06 Norgestrel and Estrogen

Clinical-pharmacological groups / Group affiliation
Anti-climacteric preparation

Active substance
estradiol valerate
norgestrel

Pharmacotherapy group:

Anticlemacteric compound (estrogen+progestagen)

Testimony Cyclo-Progynova:

  • Hormone replacement therapy for climacteric disorders,
  • involusive changes of the skin and urinary tract and genital tract, 
  • depressive conditions in the climacteric period, 
  • as well as symptoms of estrogen deficiency due to natural menopause or hypogonadism, 
  • sterilization or primary ovarian dysfunction in women with an indistant uterus; 
  • Prevention of post-menopausal osteoporosis; 
  • Normalization of irregular menstrual cycles primary or secondary amenorrhea treatment.

Method of use, course and dosage:

Taken inside.
The procedure depends on the indications and condition of the menstrual cycle.

Application for kidney disorders
The use of sex steroids can affect the biochemical performance of the kidneys.

Use in liver disorders
It is contraindicated in liver tumors currently or in anamnesis (benign or malignant); Severe liver disease.

Application in elderly patients
Use with care to avoid the risk of exacerbating chronic diseases.

Use in children
Not applicable in children.

  • Nosology (ICD codes)
  • E28.3
  • Primary ovarian failure
  • M80.0
  • Postmenopausal osteoporosis with pathological fracture
  • M80.1
  • Osteoporosis with pathological fracture after ovarian removal
  • M81.0
  • Postmenopausal osteoporosis
  • M81.1
  • Osteoporosis after ovarian removal
  • N91.0
  • Primary amenorrhea
  • N91.1
  • Secondary amenorrhea
  • N92.6
  • Irregular menstruation unspecified
  • N95.1
  • Menopause and Menopause in Women
  • N95.2
  • Postmenopausal atrophic vaginitis
  • N95.3
  • Conditions associated with artificially induced menopause

Pharmacological effect Cyclo-Progynova:

A combined hormone-based drug Cyclo-Progynova medium containing estrogen and gestagen.
Estradiol valerate is an estrogen that in humans is converted into natural 17β-estradiol.
Norgestrel is a derivative of progesterone.
Adding norgestrel for 10 days of each cycle prevents hyperplasia and endometrial cancer.
Due to the composition and cyclic pattern of the combination (taking only oestrogen for 11 days, then - combination of estrogen and gestagen for 10 days, and finally, a 7-day break), the menstrual cycle is established in women with a non-distant uterus when taking the drug Cyclo-Progynova regularly.
In the background of taking this combination there is no suppression of ovulation, and practically no change of hormone production in the body.

Features
Active substance
Pharmacological group
Formulation
Dosage mg
Pills in 1 package
Country of origin
Brand
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating